Sharekhan has given Buy recommendation for Aurobindo Pharma with a target price of Rs. 1100 in its research report issued on Mar 30, 2021
Sharekhan’s research report on Aurobindo Pharma
Expected sturdy growth in the injectables, new facility coming on stream in the US, strong new product pipeline and gradual pick up in complex generics are the key growth drivers for the US business. In order to cater to the surging demand from the Europe and emerging markets, the company is setting up a greenfield plant at Vizag, which is likely to be ready by the next 15 months. The expected commissioning of a 450mn dose vaccine capacity by end of June 2021 provides a new growth avenue for Aurobindo.
We retain Buy recommendation on the stock of Aurobindo Pharma Limited (Aurobindo)with an unchanged PT of Rs 1100.